Cabaletta Bio, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Cabaletta Bio progresses its lead CAR T therapy, rese-cel, into registrational trials for autoimmune diseases while reporting significant losses and a need for further funding.
NASDAQ
10-K: Cabaletta Bio Reports Full Year 2024 Results, Highlights Clinical Progress and Pipeline Expansion
Cabaletta Bio's 10-K filing details the company's financial results for 2024 and highlights clinical advancements in its engineered T cell therapies for autoimmune diseases.
NASDAQ
Cabaletta Bio's 10-K filing outlines its capital structure, including voting and non-voting common stock, preferred stock, pre-funded warrants, and registration rights, while also detailing regulatory and anti-takeover measures.